SNDX
Syndax Pharmaceuticals Inc
18.20$
+0.6%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +601.5% | +21.3% | +25.8% | -38.8% | -24.3% | +373.2% | +49.6% | +10.6% | +23.3% | +18.3% | -26.9% | |
| – | +607.2% | +23.3% | +23.0% | -37.5% | -25.2% | +379.5% | +50.0% | +9.2% | +18.6% | +3.8% | -12.4% | |
| – | +131.6% | +2.9% | +47.5% | -4.0% | -27.1% | +368.3% | +92.6% | -66.5% | +297.3% | -47.8% | -12.4% | |
| – | +615.1% | +20.7% | +26.5% | -39.3% | -26.1% | +390.3% | +52.5% | +8.4% | +19.2% | +0.9% | -29.0% | |
| – | +637.1% | +18.6% | +23.2% | -32.9% | -54.2% | +50.9% | +145.1% | +845.7% | -69.8% | +1,030.5% | +406.7% | |
| – | +417.6% | +812.9% | -159.8% | – | +59.3% | +215.0% | +44.8% | -155.6% | – | -81.7% | +8,849.2% | |
| – | +166.7% | +195.5% | +2.7% | +39.7% | +167.3% | -80.7% | +44.8% | +280.9% | – | – | – | |
| – | +25.2% | +7.2% | +32.1% | -6.0% | +3.3% | +51.7% | -14.7% | -27.9% | +97.0% | +644.1% | +6.5% | |
| – | -53.2% | +113.9% | +52.4% | +1.9% | +14.1% | +2.7% | +9.6% | +40.5% | +99.9% | +78.2% | +16.0% | |
| – | -71.2% | +243.4% | +85.5% | +10.0% | -96.3% | +444.1% | -86.1% | +21.3% | +138.5% | +1,103.1% | -96.3% | |
| – | +310.2% | +63.6% | -6.0% | -35.5% | +329.3% | -43.2% | +61.6% | -23.3% | +129.0% | +16.7% | +42.6% | |
| – | -99.9% | – | – | – | – | – | +11.6% | – | – | – | +3.7% | |
| – | – | +26.1% | +24.0% | -49.1% | -40.4% | +698.1% | +61.9% | +14.5% | +18.6% | -48.0% | -77.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -41.7% | +161.4% | +43.6% | +20.8% | +20.2% | +35.5% | +26.0% | +16.7% | +15.8% | +21.7% | +1.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.